SenderraRx Secures ACHC Reaccreditation with Oncology Distinction
Dallas-based SenderraRx has secured reaccreditation in specialty pharmacy from the Accreditation Commission for Health Care, marking its continued adherence to high-level safety and quality standards. The designation includes a specific distinction in oncology, recognizing the firm's specialized clinical oversight and patient support systems for those managing complex cancer therapies.
The oncology distinction validates Senderra’s model of clinical management, which emphasizes patient education, medication adherence, and direct coordination with medical care teams. CEO Will Howard noted that the company’s objective remains supporting patients through the hurdles of complex treatment regimens rather than acting solely as a medication dispenser. This ACHC milestone complements the organization's existing URAC accreditations in specialty and mail-service pharmacy, reinforcing its standing with pharmaceutical manufacturers, health plans, and pharmacy benefit managers. By maintaining these dual industry benchmarks, the pharmacy ensures its operational processes and patient service standards meet the rigorous, evidence-based requirements necessary for participation in limited-distribution programs and national specialty networks.
Comments (0)
No comments yet. Be the first!